Standard Chemical & Pharmaceutical Co (TPE:1720) Research & Development: NT$271 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1720 Standard Chemical & Pharmaceutical Co Ltd TPE:1720
93 GF Score
Price NT$57.20
GF Value NT$58.91
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Standard Chemical & Pharmaceutical Co Research & Development?

Standard Chemical & Pharmaceutical Co TPE:1720 +0.18% 93 Research & Development is NT$271 Mil as of Jun. 2026. GuruFocus rates TPE:1720 with a GF Score™ of 93/100 and a GF Value™ of NT$58.91 (Fairly Valued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Standard Chemical & Pharmaceutical Co's Research & Development for the three months ended in Jun. 2026 was NT$75 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was NT$271 Mil.

Standard Chemical & Pharmaceutical Co  (TPE:1720) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Standard Chemical & Pharmaceutical Co Research & Development Related Terms

Standard Chemical & Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Standard Chemical & Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard Chemical & Pharmaceutical Co Research & Development Chart

Standard Chemical & Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 241.79 251.88 266.27 288.09 260.36

Standard Chemical & Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.68 69.62 65.19 60.84 75.47
TPE:1720
93GF Score
Standard Chemical & Pharmaceutical Co Ltd TPE:1720
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard Chemical & Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$271 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$271 Mil mean?
Standard Chemical & Pharmaceutical Co (TPE:1720) has a Research & Development of NT$271 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Standard Chemical & Pharmaceutical Co and its competitors.
Is Standard Chemical & Pharmaceutical Co's Research & Development too high?
Standard Chemical & Pharmaceutical Co's current Research & Development is NT$271 Mil. Overall, Standard Chemical & Pharmaceutical Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard Chemical & Pharmaceutical Co's Research & Development compare to ZTS?
Standard Chemical & Pharmaceutical Co's Research & Development of NT$271 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Standard Chemical & Pharmaceutical Co and its competitors. Standard Chemical & Pharmaceutical Co's current Research & Development is NT$271 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard Chemical & Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Standard Chemical & Pharmaceutical Co (TPE:1720) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.91, compared to a current price of NT$57.20 — trading 2.9% below its estimated fair value. The current Research & Development is NT$271 Mil. Standard Chemical & Pharmaceutical Co's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Standard Chemical & Pharmaceutical Co (TPE:1720), the current Research & Development is NT$271 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard Chemical & Pharmaceutical Co (TPE:1720) Overvalued in 2026?

Based on GuruFocus' analysis, Standard Chemical & Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$57.20 is trading 2.9% below its estimated GF Value™ of NT$58.91. GuruFocus considers Standard Chemical & Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1720:

  • Research & Development: NT$271 Mil
  • GF Value™: NT$58.91 vs. price of NT$57.20 (2.9% below fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the TPE:1720 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Standard Chemical & Pharmaceutical Co Business Description

Address No.6-20,Tuku, Sinying District, Tuku Village, Tainan, TWN, 73055
Standard Chemical & Pharmaceutical Co Ltd is engaged in the manufacturing and sales of Chinese and western medicine, cosmetics, beverage, normal instruments and medical instruments. Its segments include Medicine, Dietary supplement and Ingredients. The majority of the revenue is derived from the Medicine segment. Geographically it operates in Taiwan, Japan and Others with Taiwan generating the maximum revenue.
93GF Score

Get the complete analysis for TPE:1720

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$57.20
Price
NT$58.91
GF Value